{"id":"W4400272886","doi":"10.1200/jco.2024.42.16_suppl.tps4205","title":"Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for <i>BRCA1/2</i> or <i>PALB2</i> mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Nab-paclitaxel; Internal medicine; Paclitaxel; Pancreatic ductal adenocarcinoma; Pancreatic cancer; Platinum; Cancer research; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002982229,0.002741587,0.002052315,0.0008877381,0.000612905,0.001624222,0.001920522,0.00258287,0.008729686],"category_scores_gemma":[0.001240638,0.0008508628,0.001850157,0.0006944488,0.001854821,0.001726881,0.00089575,0.00593434,0.002337508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001323877,"about_ca_system_score_gemma":0.002600367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001055337,"about_ca_topic_score_gemma":0.003067277,"domain_scores_codex":[0.9993118,0.0003463359,0.00003165707,0.0001188903,0.00005389735,0.0001374629],"domain_scores_gemma":[0.9989705,0.0001464744,0.0002069555,0.00008893062,0.0000444507,0.0005427258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8280566,0.09448789,0.002251597,0.000877897,0.001014974,0.0001550771,0.0002115194,0.002282578,0.01542269,0.0007373028,0.006365028,0.04813699],"study_design_scores_gemma":[0.7747022,0.2191568,0.001581355,0.00003146954,0.0002506525,0.0001144678,0.00004458938,0.0008927908,0.001042154,0.0004204034,0.001738111,0.000024888],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972775,0.002284354,0.001076784,0.001735755,0.0006444668,0.01227338,0.003618391,0.0003487379,0.005243147],"genre_scores_gemma":[0.9533201,0.002578879,0.005216721,0.003823358,0.0005726934,0.02065927,0.005246651,0.0001091482,0.008473236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008729686,"threshold_uncertainty_score":0.02920377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1993136341776897,"score_gpt":0.5159172287940399,"score_spread":0.3166035946163502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}